KIMBERLY YEAGER: Open Payments
NPI 1669812681 · FARMINGTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$924 in 36 payments from 10 companies in 2025. Trend: 2023 $2,240 · 2024 $1,152 · 2025 $924
Food & beverage: $822Education: $101
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 10 | $217 |
| Teva Pharmaceuticals USA, Inc. | 9 | $180 |
| Vanda Pharmaceuticals Inc. | 4 | $143 |
| E.R. Squibb & Sons, L.L.C. | 3 | $115 |
| Neurocrine BioSciences, Inc. | 2 | $80 |
| ABBVIE INC. | 4 | $77 |
| ACADIA Pharmaceuticals Inc | 1 | $46 |
| Janssen Pharmaceuticals, Inc | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Novartis Pharmaceuticals Corporation | 1 | $21 |
Products named: ARISTADA, FANAPT, COBENFY, INGREZZA, AUSTEDO XR, VRAYLAR, NUPLAZID, LYBALVI.
Industry payments across MO — which companies pay providers there.
